Itraconazole increases serum digoxin concentration

Pharmacology and Toxicology

Volumn 79, Issue 5, 1996, Pages 274-276

  Partanen, Juhani ^a   Jalava, Kirsi Maija ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; ITRACONAZOLE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGOXIN BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029944941     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1996.tb00273.x     Document Type: Article

References (21)

1. Allenmark, S., A. Edebo & K. Lindgren: Determination of itraconazole in serum with high-performance liquid chromatography and fluorescence detection. J. Chromatogr. 1990, 532, 203-206.
2. Crane, J. K. & H.-T. Shih: Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Amer. J. Med. 1993, 95, 445-446.
3. de Lannoy, I. A. M., G. Koren, K. Klein, J. Charuk & M. Silverman: Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin. Amer. J. Physiol. 1992, 263, F613-622.
4. de Lannoy, I. A. M. & M. Silverman: The MDR1 gene product, P-glycoprotein. mediates the transport of the cardiac glycoside, digoxin. Biochim. Biophys. Res. Comm. 1992, 189, 551-557.
5. Gascon, M.-P. & P. Dayer: In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur. J. Clin. Pharmacol. 1991, 41, 573-578.
6. Gault, M. H., L. L. Longerich, J. C. K. Loo, P. T. H. Ko, A. Fine, S. C. Vasdev & M. D. Dawe: Digoxin biotransformation. Clin. Pharmacol. Therap. 1984, 35, 74-82.
7. Grant, S. M. & S. P. Clissold: Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989, 37, 310-344.
8. Haria, M., H. M. Bryson & K. L. Goa: Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996, 51, 585-620.
9. Hedman, A., B. Angelin, A. Arvidsson, O. Beck, R. Dahlqvist, B. Nilsson, M. Olsson & K. Schenck-Gustafsson: Digoxin-verapamil interaction: Reduction of biliary but not renal digoxin clearance in humans. Clin. Pharmacol Therap. 1991, 49, 256-262.
10. Lewis, R. P.: Clinical use of serum digoxin concentrations. Amer. J Cardiol. 1992, 69, 97G-107G.
11. Lindenbaum, J., D. G. Rund, V P Butler, D. Tse-Eng & J. R. Saha: Inactivation of digoxin by the gut flora: Reversal by antibiotic therapy. New Engl. J. Med. 1981, 305, 789-794.
12. McClean, K. L. & G. J. Sheehan: Interaction between itraconazole and digoxin. Clin. Infect. Dis. 1994, 18, 259-260.
13. Murray, M.: P450 enzymes: Inhibition, mechanisms, genetic regulation and effects of liver disease. Clin. Pharmacokin. 1992, 23, 132-146.
14. Neuvonen, P. J. & K.-M. Jalava: Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Therap. 1996, 60, 54-61.
15. Neuvonen, P. J. & R. Suhonen: Itraconazole interacts with felodipine. J. Amer. Acad. Dermatol. 1995, 33, 134-135.
16. Olkkola, K. T., J. T. Backman & P J. Neuvonen: Midazolam should be avoided in patients receiving systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol Therap. 1994, 55, 481-485.
17. Piergies, A. A., E. M. Worwag, & A. J. Atkinson, Jr.: A concurrent audit of high digoxin plasma levels. Clin. Pharmacol. Therap. 1994, 55, 353-358.
18. Pohjola-Sintonen, S., M. Viitasalo, L. Toivonen & P. Neuvonen: Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur. J. Clin. Pharmacol. 1993, 45, 191-193.
19. Rex, J.: Itraconazole-digoxin interaction. Ann. Intern. Med. 1992, 116, 525.
20. Sachs, M. K., L. M. Blanchard & P. J. Green: Interaction of itraconazole and digoxin. Clin. Infect. Dis. 1993, 16, 400-403.
21. Varhe, A., K. T. Olkkola & P. J. Neuvonen: Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Therap. 1994, 56, 601-607.